Zanganeh Mahkam 4

What Happened
Summit Therapeutics CEO Zanganeh Mahkam made an open-market purchase of 100,000 common shares on June 4, 2026, at $14.60 per share, for a total cash outlay of $1,460,000. This is reported on a Form 4 filed the same day. Purchases (code P) are often viewed as a positive signal from insiders, though they do not prove future performance.

Key Details

• Transaction date: 2026-06-04 (open-market purchase, code P)
• Price and size: 100,000 shares at $14.60 per share; total ≈ $1,460,000
• Shares owned after transaction: Not disclosed in the filing provided
• Footnote: Reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest (per footnote F1)
• Timeliness: Reported same day as the transaction date; no late filing indicated

Context
This was a straightforward open-market buy (not an option exercise, award, or gift). The footnote disclaiming beneficial ownership is a legal statement limiting claimed control over the shares; it does not change the reported purchase. As always, insider purchases are one data point for investors and should be considered alongside company fundamentals and other information.